FEDERATED HERMES, INC. - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 310 filers reported holding CRISPR THERAPEUTICS AG in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.

Quarter-by-quarter ownership
FEDERATED HERMES, INC. ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$23,062,659
-19.3%
508,100
-0.1%
0.06%
-14.1%
Q2 2023$28,561,674
+24.1%
508,7580.0%0.07%
+22.4%
Q1 2023$23,011,124
+11.3%
508,7580.0%0.06%
+1.8%
Q4 2022$20,681,013
-37.8%
508,7580.0%0.06%
-41.2%
Q3 2022$33,247,000
-5.8%
508,758
-12.4%
0.10%
+1.0%
Q2 2022$35,302,000
-3.2%
580,9180.0%0.10%
+17.1%
Q1 2022$36,464,000
-17.2%
580,9180.0%0.08%0.0%
Q4 2021$44,022,000
-32.3%
580,9180.0%0.08%
-33.9%
Q3 2021$65,022,000
-30.9%
580,9180.0%0.12%
-29.1%
Q2 2021$94,045,000
+31.5%
580,918
-1.0%
0.18%
+25.9%
Q1 2021$71,504,000
-26.7%
586,818
-7.9%
0.14%
-30.2%
Q4 2020$97,546,000
+51.8%
637,100
-17.1%
0.20%
+31.8%
Q3 2020$64,256,000
-18.9%
768,250
-28.7%
0.15%
-23.0%
Q2 2020$79,222,000
+73.3%
1,078,0000.0%0.20%
+46.3%
Q1 2020$45,718,000
-40.5%
1,078,000
-14.6%
0.13%
-21.6%
Q4 2019$76,844,000
+117.6%
1,261,700
+46.4%
0.17%
+96.6%
Q3 2019$35,320,000
-9.8%
861,663
+3.6%
0.09%
-8.4%
Q2 2019$39,171,000
+43.5%
831,663
+8.8%
0.10%
+39.7%
Q1 2019$27,299,000
+25.0%
764,2630.0%0.07%
+13.3%
Q4 2018$21,835,000
-35.6%
764,2630.0%0.06%
-24.1%
Q3 2018$33,895,000
-8.6%
764,263
+21.0%
0.08%
-27.5%
Q2 2018$37,101,000631,4000.11%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2020
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders